Yu Xin, Zheng Heyi, Chan Matthew Tv, Wu William Kk
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, 100042, China.
Department of Anaesthesia and Intensive Care, The Chinese University of Hong KongHong Kong.
Am J Cancer Res. 2017 Sep 1;7(9):1769-1778. eCollection 2017.
Ovarian cancer accounts for the highest mortality among all gynecologic cancers. Cytoreductive surgery followed by chemotherapy with a platinum-based agent (cisplatin or carboplatin) plus paclitaxel is the first-line option for treatment of epithelial ovarian cancer. However, primary or acquired resistance to platinum-based agents is a major clinical challenge. MicroRNAs are a group of small non-coding RNAs that regulate gene expression post-transcriptionally and may function as oncogenes or tumor-suppressor genes through extensive crosstalk with intracellular signaling pathways. Importantly, their dysregulation has been implicated in ovarian tumorigenesis. Pertinent to chemotherapy, increasing evidence has revealed that miRNAs can be directly linked to chemosensitivity to platinum-based agents in ovarian cancer. In this review, we summarize current evidence concerning the role of miRNAs in prediction and modulation of cellular responses to cisplatin and carboplatin in ovarian cancer.
卵巢癌在所有妇科癌症中死亡率最高。细胞减灭术继之以含铂类药物（顺铂或卡铂）加紫杉醇的化疗是上皮性卵巢癌的一线治疗选择。然而，对铂类药物的原发性或获得性耐药是一项重大临床挑战。微小RNA是一类小的非编码RNA，它们在转录后调节基因表达，并可能通过与细胞内信号通路的广泛相互作用而作为癌基因或肿瘤抑制基因发挥作用。重要的是，它们的失调与卵巢肿瘤发生有关。与化疗相关的是，越来越多的证据表明，微小RNA可直接与卵巢癌对铂类药物的化疗敏感性相关联。在本综述中，我们总结了有关微小RNA在预测和调节卵巢癌细胞对顺铂和卡铂反应中的作用的当前证据。
